Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27676967 | 0.86 | LMNA (0.41) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL17594985 | 0.76 | MAOB (0.49) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL31261712 | 0.76 | ALDH1A1 (0.48) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL361062 | 0.75 | LTA4H (0.50) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL30041842 | 0.75 | LTA4H (0.50) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL2496116 | 0.75 | PIN1 (0.47) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL23195489 | 0.73 | MAOB (0.46) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL14973934 | 0.73 | GABRA5 (0.48) | MAPK1L3MBTL1MAOBCA12CA1 | |
| SCHEMBL12423709 | 0.73 | PIN1 (0.59) | LMNATSHRALDH1A1HPGDMAPK1 | |
| SCHEMBL1542659 | 0.73 | MAOB (0.42) | LMNATSHRALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286436-B2 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | King Faisal University (SA) | 2025-04-29 | — | — | US | disclosed |
| US-20250092048-A1 | PYRIMIDO[4,5-B]INDOLE COMPOUNDS AS CK2 INHIBITORS | UNIV KING FAISAL (SA) | 2025-03-20 | — | — | US | disclosed |
| US-12180218-B1 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | King Faisal University (SA) | 2024-12-31 | — | — | US | disclosed |
| US-11964981-B1 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | King Faisal University (SA) | 2024-04-23 | — | — | US | disclosed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| CN-102448548-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2012-05-09 | — | — | CN | disclosed |
| EP-2432554-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| CN-102256968-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2011-11-23 | — | — | CN | disclosed |
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010133528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-25 | — | — | WO | disclosed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092048-A1 | PYRIMIDO[4,5-B]INDOLE COMPOUNDS AS CK2 INHIBITORS | SKP2, CDK2, CSNK2A1 | LMNA 4391/4885TSHR 3431/4885ALDH1A1 3746/4885 |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | LMNA 2832/4885TSHR 1901/4885ALDH1A1 793/4885 |
| US-11964981-B1 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | SKP2, CDK2, CKS2 | LMNA 4000/4885TSHR 3967/4885ALDH1A1 2274/4885 |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | LMNA 2117/4885TSHR 1655/4885ALDH1A1 938/4885 |
| US-12180218-B1 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | SKP2, CSNK1A1, CSNK2A1 | LMNA 4260/4885TSHR 3552/4885ALDH1A1 2664/4885 |
| US-12286436-B2 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | SKP2, CDK2, CSNK2A1 | LMNA 4535/4885TSHR 3166/4885ALDH1A1 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.